These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7614729)

  • 1. Prospects for immunotoxin therapy of non-Hodgkin's lymphoma.
    Grossbard ML; Fidias P
    Clin Immunol Immunopathol; 1995 Aug; 76(2):107-14. PubMed ID: 7614729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A.
    Barnett MJ; Rohatiner AZ; Kingston JE; Adams KE; Batten EL; Bassan R; Thorpe PE; Horton MA; Malpas JS; Lister TA
    Haematol Blood Transfus; 1987; 31():57-8. PubMed ID: 3327786
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
    Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas.
    Lim SH; Marcus RE
    Blood Rev; 1992 Sep; 6(3):157-62. PubMed ID: 1422284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials with blocked ricin immunotoxins.
    O'Toole JE; Esseltine D; Lynch TJ; Lambert JM; Grossbard ML
    Curr Top Microbiol Immunol; 1998; 234():35-56. PubMed ID: 9670611
    [No Abstract]   [Full Text] [Related]  

  • 7. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
    Zovickian J; Johnson VG; Youle RJ
    J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-targeted therapy for low-grade lymphoma.
    Vose JM
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):15-20. PubMed ID: 10530712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
    Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
    Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R; Staak O; Borchmann P; Schwartz C; Matthey B; Hansen H; Schindler J; Ghetie V; Vitetta ES; Diehl V; Engert A
    Clin Cancer Res; 2002 Jun; 8(6):1779-86. PubMed ID: 12060617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
    Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
    Leuk Lymphoma; 1994 May; 13(5-6):441-8. PubMed ID: 8069189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients.
    Coiffier B
    Haematologica; 1999 Jun; 84 Suppl EHA-4():14-8. PubMed ID: 10907457
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
    Feuring-Buske M; Buske C; Unterhalt M; Hiddemann W
    Ann Hematol; 2000 Apr; 79(4):167-74. PubMed ID: 10834503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
    Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.
    Spitler LE; Mischak R; Scannon P
    Int J Rad Appl Instrum B; 1989; 16(6):625-7. PubMed ID: 2606718
    [No Abstract]   [Full Text] [Related]  

  • 17. [Monoclonal antibodies and immunoconjugates: new prospects in the treatment of non-Hodgkin's lymphomas].
    Sack A; Meusers P
    Strahlenther Onkol; 1999 Apr; 175(4):192-3. PubMed ID: 10230466
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic immunotoxin therapy of cancer: advances and prospects.
    Wawrzynczak EJ
    Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.
    Press OW
    Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S19-26. PubMed ID: 9672771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
    Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
    Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.